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Reply
We thank Dr. Wojcik and colleagues for their interest in our
study (1).
The apparent contradiction between our findings and their
results can be explained by at least 3 factors: difference in study
population, detection and elimination of nonpulmonary vein
(non-PV) triggers, and use of discretion of the physician in patient
selection.
Our population had predominantly nonparoxysmal atrial fibril-
lation (NPAF), compared with theirs. Most importantly, we
observed in the NPAF cohort significantly more frequent non-PV
triggers in the metabolic syndrome (MS) group compared with the
non-MS group, which is in accordance with earlier studies by
others (2). As we discussed in our study, the challenge of
eliminating non-PV triggers could have contributed to the higher
atrial tachycardia after the first procedure in patients with
lic syndrome; Non MetS  patients without metabolic syndrome.AF) or
etaborecurrence in the MS group of the NPAF cohort. Of note,
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non-PV triggers. This is likely because they did not perform any
provocative test or pharmacological challenge to disclose non-PV
triggers (which we routinely do) and missed a crucial piece of
information that limited their approach to pulmonary vein isola-
tion alone. Besides that, their study design allowed physician
discretion in selecting radiofrequency versus cryoballoon ablation.
The consequent radiofrequency cohort might have been different
from ours.
Dr. Wojcik and colleagues raise question on the homogeneity of
the study groups in terms of left atrium size (LAS). We agree that
the propensity score matching is important in reducing bias.
However, this involves the assumption of conditional indepen-
dence (i.e., selection bias is eliminated by controlling for differ-
ences in observables). We are not certain whether that assumption
is true about LAS in the context of MS. Indeed, left atrial dilation
has been proposed to be a possible mechanism for the occurrence
of atrial fibrillation (AF) in patients with MS (3). Furthermore,
many elements of MS are known to be related to increased LAS.
Therefore, we consider left atrial dilation as one of the mechanisms
of how MS affects the outcome and not a confounder.
With regard to the possible confounding effects of use of
renin-angiotensin-aldosterone blockers and statins in patients with
and without MS, it can be safely said that the claimed benefit of
these upstream drugs in preventing post-ablation AF recurrences is
not supported by strong clinical evidence. A recent randomized
trial clearly showed no effect of atorvastatin in preventing post-
ablation AF recurrences (5), and the randomized trials specifically
designed to evaluate the effect of renin-angiotensin-aldosterone
blockers on AF recurrence reported negative results (5).
Finally, we acknowledge that longer follow-up would provide
etter insight into this association.Sanghamitra Mohanty, MD
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